Information on the total number of voting rights and shares

Nyxoah SA reported an update in voting rights and share counts after issuing 146,531 new shares on June 30, 2026 from restricted share units. Total voting rights/ordinary shares now stand at 100,072,815, with 3,731,884 subscription rights not yet issued. The company also disclosed 225 convertible bonds (EUR 83,000 nominal each) and a potential 12,618,243 additional voting rights upon full conversion at EUR 1.48 per share.

Analysis

This is mainly a capitalization update, not a fundamental inflection. The important market mechanism is dilution overhang: management has already accumulated a meaningful stack of future shares through equity comp and convertibles, which lowers the torque of any operating surprise and makes per-share upside harder to sustain in a rerating. For a pre-profit medtech name, that matters less for near-term revenue and more for how aggressively investors are willing to underwrite a long-duration growth story.

The convertible layer is the more tradable issue. If the stock trends toward the conversion strike, hedging flows can become a self-limiting supply source, which tends to cap squeezes and compress multiple expansion over the next 1-3 months. By contrast, if the share price remains below conversion, this is mostly an accounting reminder rather than a cash burden, so the immediate impact on intrinsic value is limited.

Contrarian read: the market may overstate the importance of routine share-count disclosures when the real driver is still clinical/reimbursement execution. The overhang only becomes economically relevant if the company needs more external capital before a material commercial or regulatory catalyst; otherwise, the dilution is annoying but not thesis-breaking. What would falsify the cautious view is evidence that operating burn is falling fast enough to remove financing risk, or a major catalyst that re-rates the stock well beyond the conversion zone.

Key Decisions for Investors

• No immediate directional trade in NYXH; treat this as a hold/avoid until the next operating update clarifies burn and financing needs.
• Relative-value idea: long INSP / short NYXH over 1-3 months if you want sleep-apnea device exposure with less embedded dilution and cleaner upside torque.
• Set an alert around the EUR 1.48 conversion price; if NYXH trades through it, consider trimming longs or using 1-3 month put spreads to fade conversion-driven supply.
• If NYXH stays below the conversion zone and volumes remain light, there is no strong catalyst to force a short — stand aside rather than force a trade.